Sustained Gene Expression in the Retina by Improved Episomal Vectors

Overview

Journal Tissue Eng Part A

Specialties Anatomy & Histology
Biomedical Engineering
Biotechnology

Date 2014 Apr 2

PMID 24684370

Citations 9

Authors

Sofia M Calado

Ana V Oliveira

Susana Machado

Rudolf Haase

Gabriela A Silva

Affiliations

Soon will be listed here.

Abstract

Gene and cellular therapies are nowadays part of therapeutic strategies for the treatment of diverse pathologies. The drawbacks associated with gene therapy-low levels of transgene expression, vector loss during mitosis, and gene silencing-need to be addressed. The pEPI-1 and pEPito family of vectors was developed to overcome these limitations. It contains a scaffold/matrix attachment region, which anchors its replication to cell division in eukaryotic cells while in an extrachromosomal state and is less prone to silencing, due to a lower number of CpG motifs. Recent success showed that ocular gene therapy is an important tool for the treatment of several diseases, pending the overcome of the aforementioned limitations. To achieve sustained gene delivery in the retina, we evaluated several vectors based on pEPito and pEPI-1 for their ability to sustain transgene expression in retinal cells. These vectors stably transfected and replicated in retinal pigment epithelial (RPE) cells. Expression levels were promoter dependent with constitutive promoters cytomegalovirus immediate early promoter (CMV) and human CMV enhancer/human elongation factor 1 alpha promoter yielding the highest levels of transgene expression compared with the retina-specific RPE65 promoter. When injected in C57Bl6 mice, transgene expression was sustained for at least 32 days. Furthermore, the retina-specific RPE65 promoter showed higher efficiency in vivo compared to in vitro. In this study, we demonstrate that by combining tissue-specific promoters with a mitotic stable system, less susceptible to epigenetic silencing such as pEPito-based plasmids, we can achieve prolonged gene expression and a sustained therapeutic effect.

Citing Articles

Targeting miR-181a/b in retinitis pigmentosa: implications for disease progression and therapy.

Lopes da Costa B, Quinn P, Wu W, Liu S, Nolan N, Demirkol A Cell Biosci. 2024; 14(1):64.

PMID: 38773556 PMC: 11110387. DOI: 10.1186/s13578-024-01243-3.

Minicircle Delivery to the Neural Retina as a Gene Therapy Approach.

Staurenghi F, McClements M, Salman A, MacLaren R Int J Mol Sci. 2022; 23(19).

PMID: 36232975 PMC: 9569440. DOI: 10.3390/ijms231911673.

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy.

Ren D, Fisson S, Dalkara D, Ail D Pharmaceutics. 2022; 14(9).

PMID: 36145721 PMC: 9502120. DOI: 10.3390/pharmaceutics14091973.

The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases.

Toualbi L, Toms M, Moosajee M Int J Mol Sci. 2021; 22(5).

PMID: 33652562 PMC: 7956638. DOI: 10.3390/ijms22052318.

Dual-Acting Antiangiogenic Gene Therapy Reduces Inflammation and Regresses Neovascularization in Diabetic Mouse Retina.

Araujo R, Bitoque D, Silva G Mol Ther Nucleic Acids. 2020; 22:329-339.

PMID: 33230438 PMC: 7527613. DOI: 10.1016/j.omtn.2020.08.036.

References

Argyros O, Wong S, Fedonidis C, Tolmachov O, Waddington S, Howe S . Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med (Berl). 2011; 89(5):515-29. DOI: 10.1007/s00109-010-0713-3. View

Bode J, Winkelmann S, Gotze S, Spiker S, Tsutsui K, Bi C . Correlations between scaffold/matrix attachment region (S/MAR) binding activity and DNA duplex destabilization energy. J Mol Biol. 2006; 358(2):597-613. DOI: 10.1016/j.jmb.2005.11.073. View

Klausner E, Zhang Z, Wong S, Chapman R, Volin M, Harbottle R . Corneal gene delivery: chitosan oligomer as a carrier of CpG rich, CpG free or S/MAR plasmid DNA. J Gene Med. 2011; 14(2):100-8. DOI: 10.1002/jgm.1634. View

Conese M, Auriche C, Ascenzioni F . Gene therapy progress and prospects: episomally maintained self-replicating systems. Gene Ther. 2004; 11(24):1735-41. DOI: 10.1038/sj.gt.3302362. View

Reinisalo M, Putula J, Mannermaa E, Urtti A, Honkakoski P . Regulation of the human tyrosinase gene in retinal pigment epithelium cells: the significance of transcription factor orthodenticle homeobox 2 and its polymorphic binding site. Mol Vis. 2012; 18:38-54. PMC: 3258524. View

Gill D, Pringle I, Hyde S . Progress and prospects: the design and production of plasmid vectors. Gene Ther. 2009; 16(2):165-71. DOI: 10.1038/gt.2008.183. View

Le Meur G, Stieger K, Smith A, Weber M, Deschamps J, Nivard D . Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 2006; 14(4):292-303. DOI: 10.1038/sj.gt.3302861. View

Slomiany M, Rosenzweig S . IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest Ophthalmol Vis Sci. 2004; 45(8):2838-47. DOI: 10.1167/iovs.03-0565. View

Musarella M, MacDonald I . Current concepts in the treatment of retinitis pigmentosa. J Ophthalmol. 2010; 2011:753547. PMC: 2964907. DOI: 10.1155/2011/753547. View

10.

Naik R, Mukhopadhyay A, Ganguli M . Gene delivery to the retina: focus on non-viral approaches. Drug Discov Today. 2008; 14(5-6):306-15. DOI: 10.1016/j.drudis.2008.09.012. View

11.

Yew N, Zhao H, Przybylska M, Wu I, Tousignant J, Scheule R . CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther. 2002; 5(6):731-8. DOI: 10.1006/mthe.2002.0598. View

12.

Argyros O, Wong S, Niceta M, Waddington S, Howe S, Coutelle C . Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther. 2008; 15(24):1593-605. DOI: 10.1038/gt.2008.113. View

13.

Notari L, Baladron V, Aroca-Aguilar J, Balko N, Heredia R, Meyer C . Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem. 2006; 281(49):38022-37. DOI: 10.1074/jbc.M600353200. View

14.

Giannakopoulos A, Stavrou E, Zarkadis I, Zoumbos N, Thrasher A, Athanassiadou A . The functional role of S/MARs in episomal vectors as defined by the stress-induced destabilization profile of the vector sequences. J Mol Biol. 2009; 387(5):1239-49. DOI: 10.1016/j.jmb.2009.02.043. View

15.

Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps H . A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res. 1998; 27(2):426-8. PMC: 148196. DOI: 10.1093/nar/27.2.426. View

16.

Zhu D, Wu J, Spee C, Ryan S, Hinton D . BMP4 mediates oxidative stress-induced retinal pigment epithelial cell senescence and is overexpressed in age-related macular degeneration. J Biol Chem. 2009; 284(14):9529-39. PMC: 2666605. DOI: 10.1074/jbc.M809393200. View

17.

Haase R, Argyros O, Wong S, Harbottle R, Lipps H, Ogris M . pEPito: a significantly improved non-viral episomal expression vector for mammalian cells. BMC Biotechnol. 2010; 10:20. PMC: 2847955. DOI: 10.1186/1472-6750-10-20. View

18.

Wong S, Argyros O, Coutelle C, Harbottle R . Non-viral S/MAR vectors replicate episomally in vivo when provided with a selective advantage. Gene Ther. 2010; 18(1):82-7. DOI: 10.1038/gt.2010.116. View

19.

Bloquel C, Bourges J, Touchard E, Berdugo M, Benezra D, Behar-Cohen F . Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev. 2006; 58(11):1224-42. DOI: 10.1016/j.addr.2006.07.023. View

20.

Kumar-Singh R . Barriers for retinal gene therapy: separating fact from fiction. Vision Res. 2008; 48(16):1671-1680. PMC: 2538423. DOI: 10.1016/j.visres.2008.05.005. View